xRead - Nasal Obstruction (September 2024) Full Articles

20426984, 2021, 3, Downloaded from https://onlinelibrary.wiley.com/doi/10.1002/alr.22741 by Stanford University, Wiley Online Library on [01/07/2024]. See the Terms and Conditions (https://onlinelibrary.wiley.com/terms-and-conditions) on Wiley Online Library for rules of use; OA articles are governed by the applicable Creative Commons License

420

International consensus statement on rhinosinusitis

(Continues)

No benefit of topical antifungal over placebo.

No benefit of topical antifungal over placebo.

TABLE IX-35 Evidence for CRS management with topical antifungals Study Year LOE Study Design Study Groups Clinical Endpoint Conclusions Head 618 2018 1 Systematic review with meta-analysis Topical antifungal therapy Placebo Collated symptom scores QoL Adverse events No benefit of topical antifungal over placebo. Zia 1168 2019 2 RCT 20 mg amphotericin B daily (n = 29) Placebo (n = 58) CTscans Authors report improvement of CT scores. Unclear approporiateness of metric use. Jiang 1171 2018 2 RCT 20 mg amphotericin B (n = 37) Placebo (n = 36) Taiwanese SNOT-22 Endoscopic score Smell test Saccharin test No benefit of topical antifungal over placebo.

No benefit of topical antifungal over placebo.

No benefit of topical antifungal over placebo.

Acoustic rhinometry Persian RSOM-31 VAS

CT and MRI scans

Endoscopic score Cytokine levels

Lund-Mackay CT score SNAQ-11 Generic QoL score Endoscopic score Chinese RSOM

SNOT-20 score CTscore

Endoscopic score

Endoscopic scores

Hashemian 1162 2016 2 RCT 1.2 mg fluconazole daily (n = 27) Placebo (n = 24)

Yousefi 1170 2017 2 RCT 4 mg amphotericin B (n = 40) Placebo (n = 40)

Gerlinger 1169 2009 2 RCT 4 mg daily amphotericin B (n = 16) Placebo (n = 17)

Liang 1164 2008 2 RCT 20 mg amphotericin B daily (n = 51) Placebo (n = 46)